世界の軽度認知障害治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Mild Cognitive Impairment Therapeutic Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12476 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、軽度認知障害治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。軽度認知障害治療の種類別市場規模（BAN-2401、ボスチニブ、ブレキサノロン、CSP-1103、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・軽度認知障害治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AgeneBio Inc、Avraham Pharmaceuticals Ltd、CereSpir Inc、ConSynance Therapeutics Inc、Eisai Co Ltd、Eli Lilly and Company、Ensol Biosciences Inc、Genzyme Corp、IntelGenx Corp、Krenitsky Pharmaceuticals Inc、Merck & Co Inc、Nanotherapeutics Inc、Neuron Biopharma SA、Pfizer Inc、Sage Therapeutics Inc、SBI Pharmaceuticals Co Ltd、Suven Life Sciences Ltd、Takeda Pharmaceutical Company Ltd、Therapix Biosciences Ltd ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：BAN-2401、ボスチニブ、ブレキサノロン、CSP-1103、その他 ・用途別分析2016年-2026年：病院、クリニック、その他 ・軽度認知障害治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・軽度認知障害治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・軽度認知障害治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・軽度認知障害治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・軽度認知障害治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Mild Cognitive Impairment Therapeutic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Mild Cognitive Impairment Therapeutic size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Mild Cognitive Impairment Therapeutic market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Mild Cognitive Impairment Therapeutic market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
BAN-2401
Bosutinib
Brexanolone
CSP-1103
Others

Market segment by Application, can be divided into
Hospital
Clinic
Others

Market segment by players, this report covers
AgeneBio Inc
Avraham Pharmaceuticals Ltd
CereSpir Inc
ConSynance Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Company
Ensol Biosciences Inc
Genzyme Corp
IntelGenx Corp
Krenitsky Pharmaceuticals Inc
Merck & Co Inc
Nanotherapeutics Inc
Neuron Biopharma SA
Pfizer Inc
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Suven Life Sciences Ltd
Takeda Pharmaceutical Company Ltd
Therapix Biosciences Ltd

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Mild Cognitive Impairment Therapeutic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Mild Cognitive Impairment Therapeutic, with revenue, gross margin and global market share of Mild Cognitive Impairment Therapeutic from 2019 to 2021.
Chapter 3, the Mild Cognitive Impairment Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Mild Cognitive Impairment Therapeutic market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Mild Cognitive Impairment Therapeutic research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Mild Cognitive Impairment Therapeutic
1.2 Classification of Mild Cognitive Impairment Therapeutic by Type
1.2.1 Overview: Global Mild Cognitive Impairment Therapeutic Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Type in 2020
1.2.3 BAN-2401
1.2.4 Bosutinib
1.2.5 Brexanolone
1.2.6 CSP-1103
1.2.7 Others
1.3 Global Mild Cognitive Impairment Therapeutic Market by Application
1.3.1 Overview: Global Mild Cognitive Impairment Therapeutic Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Mild Cognitive Impairment Therapeutic Market Size & Forecast
1.5 Global Mild Cognitive Impairment Therapeutic Market Size and Forecast by Region
1.5.1 Global Mild Cognitive Impairment Therapeutic Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Mild Cognitive Impairment Therapeutic Market Size by Region, (2016-2021)
1.5.3 North America Mild Cognitive Impairment Therapeutic Market Size and Prospect (2016-2026)
1.5.4 Europe Mild Cognitive Impairment Therapeutic Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size and Prospect (2016-2026)
1.5.6 South America Mild Cognitive Impairment Therapeutic Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Mild Cognitive Impairment Therapeutic Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Mild Cognitive Impairment Therapeutic Market Drivers
1.6.2 Mild Cognitive Impairment Therapeutic Market Restraints
1.6.3 Mild Cognitive Impairment Therapeutic Trends Analysis
2 Company Profiles
2.1 AgeneBio Inc
2.1.1 AgeneBio Inc Details
2.1.2 AgeneBio Inc Major Business
2.1.3 AgeneBio Inc Mild Cognitive Impairment Therapeutic Product and Solutions
2.1.4 AgeneBio Inc Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AgeneBio Inc Recent Developments and Future Plans
2.2 Avraham Pharmaceuticals Ltd
2.2.1 Avraham Pharmaceuticals Ltd Details
2.2.2 Avraham Pharmaceuticals Ltd Major Business
2.2.3 Avraham Pharmaceuticals Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
2.2.4 Avraham Pharmaceuticals Ltd Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Avraham Pharmaceuticals Ltd Recent Developments and Future Plans
2.3 CereSpir Inc
2.3.1 CereSpir Inc Details
2.3.2 CereSpir Inc Major Business
2.3.3 CereSpir Inc Mild Cognitive Impairment Therapeutic Product and Solutions
2.3.4 CereSpir Inc Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 CereSpir Inc Recent Developments and Future Plans
2.4 ConSynance Therapeutics Inc
2.4.1 ConSynance Therapeutics Inc Details
2.4.2 ConSynance Therapeutics Inc Major Business
2.4.3 ConSynance Therapeutics Inc Mild Cognitive Impairment Therapeutic Product and Solutions
2.4.4 ConSynance Therapeutics Inc Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 ConSynance Therapeutics Inc Recent Developments and Future Plans
2.5 Eisai Co Ltd
2.5.1 Eisai Co Ltd Details
2.5.2 Eisai Co Ltd Major Business
2.5.3 Eisai Co Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
2.5.4 Eisai Co Ltd Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Eisai Co Ltd Recent Developments and Future Plans
2.6 Eli Lilly and Company
2.6.1 Eli Lilly and Company Details
2.6.2 Eli Lilly and Company Major Business
2.6.3 Eli Lilly and Company Mild Cognitive Impairment Therapeutic Product and Solutions
2.6.4 Eli Lilly and Company Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Eli Lilly and Company Recent Developments and Future Plans
2.7 Ensol Biosciences Inc
2.7.1 Ensol Biosciences Inc Details
2.7.2 Ensol Biosciences Inc Major Business
2.7.3 Ensol Biosciences Inc Mild Cognitive Impairment Therapeutic Product and Solutions
2.7.4 Ensol Biosciences Inc Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Ensol Biosciences Inc Recent Developments and Future Plans
2.8 Genzyme Corp
2.8.1 Genzyme Corp Details
2.8.2 Genzyme Corp Major Business
2.8.3 Genzyme Corp Mild Cognitive Impairment Therapeutic Product and Solutions
2.8.4 Genzyme Corp Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Genzyme Corp Recent Developments and Future Plans
2.9 IntelGenx Corp
2.9.1 IntelGenx Corp Details
2.9.2 IntelGenx Corp Major Business
2.9.3 IntelGenx Corp Mild Cognitive Impairment Therapeutic Product and Solutions
2.9.4 IntelGenx Corp Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 IntelGenx Corp Recent Developments and Future Plans
2.10 Krenitsky Pharmaceuticals Inc
2.10.1 Krenitsky Pharmaceuticals Inc Details
2.10.2 Krenitsky Pharmaceuticals Inc Major Business
2.10.3 Krenitsky Pharmaceuticals Inc Mild Cognitive Impairment Therapeutic Product and Solutions
2.10.4 Krenitsky Pharmaceuticals Inc Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Krenitsky Pharmaceuticals Inc Recent Developments and Future Plans
2.11 Merck & Co Inc
2.11.1 Merck & Co Inc Details
2.11.2 Merck & Co Inc Major Business
2.11.3 Merck & Co Inc Mild Cognitive Impairment Therapeutic Product and Solutions
2.11.4 Merck & Co Inc Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Merck & Co Inc Recent Developments and Future Plans
2.12 Nanotherapeutics Inc
2.12.1 Nanotherapeutics Inc Details
2.12.2 Nanotherapeutics Inc Major Business
2.12.3 Nanotherapeutics Inc Mild Cognitive Impairment Therapeutic Product and Solutions
2.12.4 Nanotherapeutics Inc Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Nanotherapeutics Inc Recent Developments and Future Plans
2.13 Neuron Biopharma SA
2.13.1 Neuron Biopharma SA Details
2.13.2 Neuron Biopharma SA Major Business
2.13.3 Neuron Biopharma SA Mild Cognitive Impairment Therapeutic Product and Solutions
2.13.4 Neuron Biopharma SA Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Neuron Biopharma SA Recent Developments and Future Plans
2.14 Pfizer Inc
2.14.1 Pfizer Inc Details
2.14.2 Pfizer Inc Major Business
2.14.3 Pfizer Inc Mild Cognitive Impairment Therapeutic Product and Solutions
2.14.4 Pfizer Inc Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Pfizer Inc Recent Developments and Future Plans
2.15 Sage Therapeutics Inc
2.15.1 Sage Therapeutics Inc Details
2.15.2 Sage Therapeutics Inc Major Business
2.15.3 Sage Therapeutics Inc Mild Cognitive Impairment Therapeutic Product and Solutions
2.15.4 Sage Therapeutics Inc Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Sage Therapeutics Inc Recent Developments and Future Plans
2.16 SBI Pharmaceuticals Co Ltd
2.16.1 SBI Pharmaceuticals Co Ltd Details
2.16.2 SBI Pharmaceuticals Co Ltd Major Business
2.16.3 SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
2.16.4 SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 SBI Pharmaceuticals Co Ltd Recent Developments and Future Plans
2.17 Suven Life Sciences Ltd
2.17.1 Suven Life Sciences Ltd Details
2.17.2 Suven Life Sciences Ltd Major Business
2.17.3 Suven Life Sciences Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
2.17.4 Suven Life Sciences Ltd Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Suven Life Sciences Ltd Recent Developments and Future Plans
2.18 Takeda Pharmaceutical Company Ltd
2.18.1 Takeda Pharmaceutical Company Ltd Details
2.18.2 Takeda Pharmaceutical Company Ltd Major Business
2.18.3 Takeda Pharmaceutical Company Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
2.18.4 Takeda Pharmaceutical Company Ltd Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Takeda Pharmaceutical Company Ltd Recent Developments and Future Plans
2.19 Therapix Biosciences Ltd
2.19.1 Therapix Biosciences Ltd Details
2.19.2 Therapix Biosciences Ltd Major Business
2.19.3 Therapix Biosciences Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
2.19.4 Therapix Biosciences Ltd Mild Cognitive Impairment Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Therapix Biosciences Ltd Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Mild Cognitive Impairment Therapeutic Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Mild Cognitive Impairment Therapeutic Players Market Share
3.2.2 Top 10 Mild Cognitive Impairment Therapeutic Players Market Share
3.2.3 Market Competition Trend
3.3 Mild Cognitive Impairment Therapeutic Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Mild Cognitive Impairment Therapeutic Revenue and Market Share by Type (2016-2021)
4.2 Global Mild Cognitive Impairment Therapeutic Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Application (2016-2021)
5.2 Mild Cognitive Impairment Therapeutic Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Mild Cognitive Impairment Therapeutic Revenue by Type (2016-2026)
6.2 North America Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2026)
6.3 North America Mild Cognitive Impairment Therapeutic Market Size by Country
6.3.1 North America Mild Cognitive Impairment Therapeutic Revenue by Country (2016-2026)
6.3.2 United States Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
6.3.3 Canada Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
6.3.4 Mexico Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Mild Cognitive Impairment Therapeutic Revenue by Type (2016-2026)
7.2 Europe Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2026)
7.3 Europe Mild Cognitive Impairment Therapeutic Market Size by Country
7.3.1 Europe Mild Cognitive Impairment Therapeutic Revenue by Country (2016-2026)
7.3.2 Germany Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
7.3.3 France Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
7.3.5 Russia Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
7.3.6 Italy Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue by Type (2016-2026)
8.2 Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2026)
8.3 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Region
8.3.1 Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue by Region (2016-2026)
8.3.2 China Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
8.3.3 Japan Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
8.3.4 South Korea Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
8.3.5 India Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
8.3.7 Australia Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Mild Cognitive Impairment Therapeutic Revenue by Type (2016-2026)
9.2 South America Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2026)
9.3 South America Mild Cognitive Impairment Therapeutic Market Size by Country
9.3.1 South America Mild Cognitive Impairment Therapeutic Revenue by Country (2016-2026)
9.3.2 Brazil Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
9.3.3 Argentina Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Mild Cognitive Impairment Therapeutic Revenue by Type (2016-2026)
10.2 Middle East & Africa Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2026)
10.3 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Country
10.3.1 Middle East & Africa Mild Cognitive Impairment Therapeutic Revenue by Country (2016-2026)
10.3.2 Turkey Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
10.3.4 UAE Mild Cognitive Impairment Therapeutic Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Mild Cognitive Impairment Therapeutic Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Mild Cognitive Impairment Therapeutic Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Mild Cognitive Impairment Therapeutic Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Mild Cognitive Impairment Therapeutic Revenue (USD Million) by Region (2016-2021)
Table 5. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Region (2021-2026)
Table 6. AgeneBio Inc Corporate Information, Head Office, and Major Competitors
Table 7. AgeneBio Inc Major Business
Table 8. AgeneBio Inc Mild Cognitive Impairment Therapeutic Product and Solutions
Table 9. AgeneBio Inc Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Avraham Pharmaceuticals Ltd Corporate Information, Head Office, and Major Competitors
Table 11. Avraham Pharmaceuticals Ltd Major Business
Table 12. Avraham Pharmaceuticals Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
Table 13. Avraham Pharmaceuticals Ltd Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. CereSpir Inc Corporate Information, Head Office, and Major Competitors
Table 15. CereSpir Inc Major Business
Table 16. CereSpir Inc Mild Cognitive Impairment Therapeutic Product and Solutions
Table 17. CereSpir Inc Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. ConSynance Therapeutics Inc Corporate Information, Head Office, and Major Competitors
Table 19. ConSynance Therapeutics Inc Major Business
Table 20. ConSynance Therapeutics Inc Mild Cognitive Impairment Therapeutic Product and Solutions
Table 21. ConSynance Therapeutics Inc Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Eisai Co Ltd Corporate Information, Head Office, and Major Competitors
Table 23. Eisai Co Ltd Major Business
Table 24. Eisai Co Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
Table 25. Eisai Co Ltd Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 27. Eli Lilly and Company Major Business
Table 28. Eli Lilly and Company Mild Cognitive Impairment Therapeutic Product and Solutions
Table 29. Eli Lilly and Company Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Ensol Biosciences Inc Corporate Information, Head Office, and Major Competitors
Table 31. Ensol Biosciences Inc Major Business
Table 32. Ensol Biosciences Inc Mild Cognitive Impairment Therapeutic Product and Solutions
Table 33. Ensol Biosciences Inc Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Genzyme Corp Corporate Information, Head Office, and Major Competitors
Table 35. Genzyme Corp Major Business
Table 36. Genzyme Corp Mild Cognitive Impairment Therapeutic Product and Solutions
Table 37. Genzyme Corp Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. IntelGenx Corp Corporate Information, Head Office, and Major Competitors
Table 39. IntelGenx Corp Major Business
Table 40. IntelGenx Corp Mild Cognitive Impairment Therapeutic Product and Solutions
Table 41. IntelGenx Corp Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Krenitsky Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 43. Krenitsky Pharmaceuticals Inc Major Business
Table 44. Krenitsky Pharmaceuticals Inc Mild Cognitive Impairment Therapeutic Product and Solutions
Table 45. Krenitsky Pharmaceuticals Inc Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Merck & Co Inc Corporate Information, Head Office, and Major Competitors
Table 47. Merck & Co Inc Major Business
Table 48. Merck & Co Inc Mild Cognitive Impairment Therapeutic Product and Solutions
Table 49. Merck & Co Inc Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Nanotherapeutics Inc Corporate Information, Head Office, and Major Competitors
Table 51. Nanotherapeutics Inc Major Business
Table 52. Nanotherapeutics Inc Mild Cognitive Impairment Therapeutic Product and Solutions
Table 53. Nanotherapeutics Inc Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Neuron Biopharma SA Corporate Information, Head Office, and Major Competitors
Table 55. Neuron Biopharma SA Major Business
Table 56. Neuron Biopharma SA Mild Cognitive Impairment Therapeutic Product and Solutions
Table 57. Neuron Biopharma SA Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Pfizer Inc Corporate Information, Head Office, and Major Competitors
Table 59. Pfizer Inc Major Business
Table 60. Pfizer Inc Mild Cognitive Impairment Therapeutic Product and Solutions
Table 61. Pfizer Inc Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Sage Therapeutics Inc Corporate Information, Head Office, and Major Competitors
Table 63. Sage Therapeutics Inc Major Business
Table 64. Sage Therapeutics Inc Mild Cognitive Impairment Therapeutic Product and Solutions
Table 65. Sage Therapeutics Inc Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. SBI Pharmaceuticals Co Ltd Corporate Information, Head Office, and Major Competitors
Table 67. SBI Pharmaceuticals Co Ltd Major Business
Table 68. SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
Table 69. SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Suven Life Sciences Ltd Corporate Information, Head Office, and Major Competitors
Table 71. Suven Life Sciences Ltd Major Business
Table 72. Suven Life Sciences Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
Table 73. Suven Life Sciences Ltd Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Takeda Pharmaceutical Company Ltd Corporate Information, Head Office, and Major Competitors
Table 75. Takeda Pharmaceutical Company Ltd Major Business
Table 76. Takeda Pharmaceutical Company Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
Table 77. Takeda Pharmaceutical Company Ltd Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Therapix Biosciences Ltd Corporate Information, Head Office, and Major Competitors
Table 79. Therapix Biosciences Ltd Major Business
Table 80. Therapix Biosciences Ltd Mild Cognitive Impairment Therapeutic Product and Solutions
Table 81. Therapix Biosciences Ltd Mild Cognitive Impairment Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Global Mild Cognitive Impairment Therapeutic Revenue (USD Million) by Players (2019-2021)
Table 83. Global Mild Cognitive Impairment Therapeutic Revenue Share by Players (2019-2021)
Table 84. Breakdown of Mild Cognitive Impairment Therapeutic by Company Type (Tier 1, Tier 2 and Tier 3)
Table 85. Mild Cognitive Impairment Therapeutic Players Head Office, Products and Services Provided
Table 86. Mild Cognitive Impairment Therapeutic Mergers & Acquisitions in the Past Five Years
Table 87. Mild Cognitive Impairment Therapeutic New Entrants and Expansion Plans
Table 88. Global Mild Cognitive Impairment Therapeutic Revenue (USD Million) by Type (2016-2021)
Table 89. Global Mild Cognitive Impairment Therapeutic Revenue Share by Type (2016-2021)
Table 90. Global Mild Cognitive Impairment Therapeutic Revenue Forecast by Type (2021-2026)
Table 91. Global Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2021)
Table 92. Global Mild Cognitive Impairment Therapeutic Revenue Forecast by Application (2021-2026)
Table 93. North America Mild Cognitive Impairment Therapeutic Revenue by Type (2016-2021) & (USD Million)
Table 94. North America Mild Cognitive Impairment Therapeutic Revenue by Type (2021-2026) & (USD Million)
Table 95. North America Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2021) & (USD Million)
Table 96. North America Mild Cognitive Impairment Therapeutic Revenue by Application (2021-2026) & (USD Million)
Table 97. North America Mild Cognitive Impairment Therapeutic Revenue by Country (2016-2021) & (USD Million)
Table 98. North America Mild Cognitive Impairment Therapeutic Revenue by Country (2021-2026) & (USD Million)
Table 99. Europe Mild Cognitive Impairment Therapeutic Revenue by Type (2016-2021) & (USD Million)
Table 100. Europe Mild Cognitive Impairment Therapeutic Revenue by Type (2021-2026) & (USD Million)
Table 101. Europe Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2021) & (USD Million)
Table 102. Europe Mild Cognitive Impairment Therapeutic Revenue by Application (2021-2026) & (USD Million)
Table 103. Europe Mild Cognitive Impairment Therapeutic Revenue by Country (2016-2021) & (USD Million)
Table 104. Europe Mild Cognitive Impairment Therapeutic Revenue by Country (2021-2026) & (USD Million)
Table 105. Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue by Type (2016-2021) & (USD Million)
Table 106. Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue by Type (2021-2026) & (USD Million)
Table 107. Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2021) & (USD Million)
Table 108. Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue by Application (2021-2026) & (USD Million)
Table 109. Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue by Region (2016-2021) & (USD Million)
Table 110. Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue by Region (2021-2026) & (USD Million)
Table 111. South America Mild Cognitive Impairment Therapeutic Revenue by Type (2016-2021) & (USD Million)
Table 112. South America Mild Cognitive Impairment Therapeutic Revenue by Type (2021-2026) & (USD Million)
Table 113. South America Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2021) & (USD Million)
Table 114. South America Mild Cognitive Impairment Therapeutic Revenue by Application (2021-2026) & (USD Million)
Table 115. South America Mild Cognitive Impairment Therapeutic Revenue by Country (2016-2021) & (USD Million)
Table 116. South America Mild Cognitive Impairment Therapeutic Revenue by Country (2021-2026) & (USD Million)
Table 117. Middle East & Africa Mild Cognitive Impairment Therapeutic Revenue by Type (2016-2021) & (USD Million)
Table 118. Middle East & Africa Mild Cognitive Impairment Therapeutic Revenue by Type (2021-2026) & (USD Million)
Table 119. Middle East & Africa Mild Cognitive Impairment Therapeutic Revenue by Application (2016-2021) & (USD Million)
Table 120. Middle East & Africa Mild Cognitive Impairment Therapeutic Revenue by Application (2021-2026) & (USD Million)
Table 121. Middle East & Africa Mild Cognitive Impairment Therapeutic Revenue by Country (2016-2021) & (USD Million)
Table 122. Middle East & Africa Mild Cognitive Impairment Therapeutic Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Mild Cognitive Impairment Therapeutic Picture
Figure 2. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Type in 2020
Figure 3. BAN-2401
Figure 4. Bosutinib
Figure 5. Brexanolone
Figure 6. CSP-1103
Figure 7. Others
Figure 8. Mild Cognitive Impairment Therapeutic Revenue Market Share by Application in 2020
Figure 9. Hospital Picture
Figure 10. Clinic Picture
Figure 11. Others Picture
Figure 12. Global Mild Cognitive Impairment Therapeutic Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Mild Cognitive Impairment Therapeutic Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Region (2016-2026)
Figure 15. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Region in 2020
Figure 16. North America Mild Cognitive Impairment Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Mild Cognitive Impairment Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Mild Cognitive Impairment Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Mild Cognitive Impairment Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Mild Cognitive Impairment Therapeutic Market Drivers
Figure 22. Mild Cognitive Impairment Therapeutic Market Restraints
Figure 23. Mild Cognitive Impairment Therapeutic Market Trends
Figure 24. AgeneBio Inc Recent Developments and Future Plans
Figure 25. Avraham Pharmaceuticals Ltd Recent Developments and Future Plans
Figure 26. CereSpir Inc Recent Developments and Future Plans
Figure 27. ConSynance Therapeutics Inc Recent Developments and Future Plans
Figure 28. Eisai Co Ltd Recent Developments and Future Plans
Figure 29. Eli Lilly and Company Recent Developments and Future Plans
Figure 30. Ensol Biosciences Inc Recent Developments and Future Plans
Figure 31. Genzyme Corp Recent Developments and Future Plans
Figure 32. IntelGenx Corp Recent Developments and Future Plans
Figure 33. Krenitsky Pharmaceuticals Inc Recent Developments and Future Plans
Figure 34. Merck & Co Inc Recent Developments and Future Plans
Figure 35. Nanotherapeutics Inc Recent Developments and Future Plans
Figure 36. Neuron Biopharma SA Recent Developments and Future Plans
Figure 37. Pfizer Inc Recent Developments and Future Plans
Figure 38. Sage Therapeutics Inc Recent Developments and Future Plans
Figure 39. SBI Pharmaceuticals Co Ltd Recent Developments and Future Plans
Figure 40. Suven Life Sciences Ltd Recent Developments and Future Plans
Figure 41. Takeda Pharmaceutical Company Ltd Recent Developments and Future Plans
Figure 42. Therapix Biosciences Ltd Recent Developments and Future Plans
Figure 43. Global Mild Cognitive Impairment Therapeutic Revenue Share by Players in 2020
Figure 44. Mild Cognitive Impairment Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 45. Global Top 3 Players Mild Cognitive Impairment Therapeutic Revenue Market Share in 2020
Figure 46. Global Top 10 Players Mild Cognitive Impairment Therapeutic Revenue Market Share in 2020
Figure 47. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 48. Global Mild Cognitive Impairment Therapeutic Revenue Share by Type in 2020
Figure 49. Global Mild Cognitive Impairment Therapeutic Market Share Forecast by Type (2021-2026)
Figure 50. Global Mild Cognitive Impairment Therapeutic Revenue Share by Application in 2020
Figure 51. Global Mild Cognitive Impairment Therapeutic Market Share Forecast by Application (2021-2026)
Figure 52. North America Mild Cognitive Impairment Therapeutic Sales Market Share by Type (2016-2026)
Figure 53. North America Mild Cognitive Impairment Therapeutic Sales Market Share by Application (2016-2026)
Figure 54. North America Mild Cognitive Impairment Therapeutic Revenue Market Share by Country (2016-2026)
Figure 55. United States Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Canada Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Mexico Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Europe Mild Cognitive Impairment Therapeutic Sales Market Share by Type (2016-2026)
Figure 59. Europe Mild Cognitive Impairment Therapeutic Sales Market Share by Application (2016-2026)
Figure 60. Europe Mild Cognitive Impairment Therapeutic Revenue Market Share by Country (2016-2026)
Figure 61. Germany Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. France Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. United Kingdom Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Russia Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Italy Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Asia-Pacific Mild Cognitive Impairment Therapeutic Sales Market Share by Type (2016-2026)
Figure 67. Asia-Pacific Mild Cognitive Impairment Therapeutic Sales Market Share by Application (2016-2026)
Figure 68. Asia-Pacific Mild Cognitive Impairment Therapeutic Revenue Market Share by Region (2016-2026)
Figure 69. China Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Japan Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. South Korea Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. India Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Southeast Asia Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Australia Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. South America Mild Cognitive Impairment Therapeutic Sales Market Share by Type (2016-2026)
Figure 76. South America Mild Cognitive Impairment Therapeutic Sales Market Share by Application (2016-2026)
Figure 77. South America Mild Cognitive Impairment Therapeutic Revenue Market Share by Country (2016-2026)
Figure 78. Brazil Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Argentina Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Middle East and Africa Mild Cognitive Impairment Therapeutic Sales Market Share by Type (2016-2026)
Figure 81. Middle East and Africa Mild Cognitive Impairment Therapeutic Sales Market Share by Application (2016-2026)
Figure 82. Middle East and Africa Mild Cognitive Impairment Therapeutic Revenue Market Share by Country (2016-2026)
Figure 83. Turkey Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 84. Saudi Arabia Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. UAE Mild Cognitive Impairment Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. Methodology
Figure 87. Research Process and Data Source

---